Victory Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Victory Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.88M	Buy	64,225 +14,255	+29%	+$791K	﹤0.01%	1446
2026 Q1	$2.91M	Buy	+49,970	New	+$2.3M	﹤0.01%	1502
2023 Q3	–	Sell	-6,500	Closed	-$250K	–	2562
2023 Q2	$250K	Sell	6,500 -21,690	-77%	-$862K	﹤0.01%	2153
2023 Q1	$1.01M	Buy	+28,190	New	+$1.04M	﹤0.01%	1688
2022 Q4	–	Sell	-12,228	Closed	-$441K	–	2721
2022 Q3	$441K	Sell	12,228 -910	-7%	-$32.7K	﹤0.01%	2102
2022 Q2	$400K	Sell	13,138 -1,126	-8%	-$34.1K	﹤0.01%	2147
2022 Q1	$403K	Buy	14,264 +6,719	+89%	+$201K	﹤0.01%	2205
2021 Q4	$236K	Buy	+7,545	New	+$225K	﹤0.01%	2441

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Victory Capital Management's XENE Position: Q2 2026 in Review

Victory Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 29% in Q2 2026, buying an estimated $791K and bringing the position to 64,225 shares worth $3.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

Victory Capital Management first reported a position in XENE in Q4 2021 and has held it in 8 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Victory Capital Management held 64,225 shares of Xenon Pharmaceuticals worth $3.88M as of Q2 2026.
Victory Capital Management bought 14,255 Xenon Pharmaceuticals shares in Q2 2026, an estimated $791K.
Xenon Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1446 holding.
Victory Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.